PLRX Quote, Financials, Valuation and Earnings

GE HealthCare Technologies has a net margin of -- compared to Pliant Therapeutics's net margin of 13.56%. Pliant Therapeutics's return on equity of -- beat GE HealthCare Technologies's return on equity of 24.88%.

Pliant Therapeutics has a consensus price target of $10.06, signalling upside risk potential of 650.93%. On the other hand GE HealthCare Technologies has an analysts' consensus of $100.23 which suggests that it could grow by 59.57%. Given that Pliant Therapeutics has higher upside potential than GE HealthCare Technologies, analysts believe Pliant Therapeutics is more attractive than GE HealthCare Technologies.

Pliant Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GE HealthCare Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pliant Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GE HealthCare Technologies offers a yield of 0.2% to investors and pays a quarterly dividend of $0.04 per share. Pliant Therapeutics pays -- of its earnings as a dividend. GE HealthCare Technologies pays out 2.76% of its earnings as a dividend. GE HealthCare Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pliant Therapeutics quarterly revenues are --, which are smaller than GE HealthCare Technologies quarterly revenues of $5.3B. Pliant Therapeutics's net income of -$49.7M is lower than GE HealthCare Technologies's net income of $721M. Notably, Pliant Therapeutics's price-to-earnings ratio is -- while GE HealthCare Technologies's PE ratio is 14.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics is 16.14x versus 1.47x for GE HealthCare Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Neumora Therapeutics has a net margin of -- compared to Pliant Therapeutics's net margin of --. Pliant Therapeutics's return on equity of -- beat Neumora Therapeutics's return on equity of --.

Pliant Therapeutics has a consensus price target of $10.06, signalling upside risk potential of 650.93%. On the other hand Neumora Therapeutics has an analysts' consensus of $6.29 which suggests that it could grow by 822.56%. Given that Neumora Therapeutics has higher upside potential than Pliant Therapeutics, analysts believe Neumora Therapeutics is more attractive than Pliant Therapeutics.

Pliant Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Neumora Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pliant Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neumora Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics pays -- of its earnings as a dividend. Neumora Therapeutics pays out -- of its earnings as a dividend.

Pliant Therapeutics quarterly revenues are --, which are smaller than Neumora Therapeutics quarterly revenues of --. Pliant Therapeutics's net income of -$49.7M is higher than Neumora Therapeutics's net income of -$58.8M. Notably, Pliant Therapeutics's price-to-earnings ratio is -- while Neumora Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics is 16.14x versus -- for Neumora Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Acelyrin has a net margin of -- compared to Pliant Therapeutics's net margin of --. Pliant Therapeutics's return on equity of -- beat Acelyrin's return on equity of --.

Pliant Therapeutics has a consensus price target of $10.06, signalling upside risk potential of 650.93%. On the other hand Acelyrin has an analysts' consensus of $8.00 which suggests that it could grow by 258.74%. Given that Pliant Therapeutics has higher upside potential than Acelyrin, analysts believe Pliant Therapeutics is more attractive than Acelyrin.

Pliant Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Acelyrin has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pliant Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Acelyrin offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics pays -- of its earnings as a dividend. Acelyrin pays out -- of its earnings as a dividend.

Pliant Therapeutics quarterly revenues are --, which are smaller than Acelyrin quarterly revenues of --. Pliant Therapeutics's net income of -$49.7M is higher than Acelyrin's net income of -$79M. Notably, Pliant Therapeutics's price-to-earnings ratio is -- while Acelyrin's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics is 16.14x versus -- for Acelyrin. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of -- compared to Pliant Therapeutics's net margin of -125.59%. Pliant Therapeutics's return on equity of -- beat SpringWorks Therapeutics's return on equity of -46.69%.

Pliant Therapeutics has a consensus price target of $10.06, signalling upside risk potential of 650.93%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $72.88 which suggests that it could grow by 99.82%. Given that Pliant Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Pliant Therapeutics is more attractive than SpringWorks Therapeutics.

Pliant Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.261%.

Pliant Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

Pliant Therapeutics quarterly revenues are --, which are smaller than SpringWorks Therapeutics quarterly revenues of $61.5M. Pliant Therapeutics's net income of -$49.7M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, Pliant Therapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics is 16.14x versus 14.11x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.